health economics • outcomes research • disease modeling • prostate cancer • cost-effectiveness evaluation
My research focuses on improving the manner in which healthcare is delivered to patients, particularly for those with prostate cancer or other urological cancers, and for finding ways to optimize cost allocation for services. Specifically, significant advances have been made in the field of prostate cancer, including new health technologies for surgery and radiation therapies for localized prostate cancers, and many innovative drugs and chemotherapies for advanced stage. Furthermore, new tests have demonstrated clinical utility and benefits in the screening, diagnosis or treatment phase of prostate cancer. Due to economic consideration or lack of cost-effectiveness evidence, many of these advances are not accessible to the general population. My research program focuses on the analysis of health service utilization and associated costs vs. benefits (clinical outcomes) from diagnosis and over the entire course of the disease in real-life settings, using administrative databases or simulation models, such as Markov models with Monte-Carlo microsimulations.
Sanyal C, Aprikian A, Cury F, Chevalier S, Dragomir A. Clinical management and burden of prostate cancer: a Markov Monte Carlo model. PLoS One. 2014 Dec 4;9(12):e113432. doi: 10.1371/journal.pone.0113432. eCollection 2014. PMID: 25474006.
Dragomir A, Cury FL, Aprikian AG. Active surveillance for low-risk prostate cancer compared with immediate treatment: a Canadian cost comparison. CMAJ Open. 2014 Apr 24;2(2):E60-8. doi: 10.9778/cmajo.20130037. eCollection 2014 Apr. PMID: 25077131.
Dragomir A, Dinea D, Vanhuyse M, Cury FL, Aprikian AG. Drug costs in the management of metastatic castration-resistant prostate cancer in Canada. BMC Health Serv Res. 2014 Jun 13;14:252. doi: 10.1186/1472-6963-14-252. PMID: 24927758.
Bachir BG, Dragomir A, Aprikian AG, Tanguay S, Fairey A, Kulkarni GS, Breau RH, Black PC, Kassouf W. Contemporary cost-effectiveness analysis comparing sequential bacillus Calmette-Guerin and electromotive mitomycin versus bacillus Calmette-Guerin alone for patients with high-risk non-muscle-invasive bladder cancer. Cancer. 2014 Aug 15;120(16):2424-31. doi: 10.1002/cncr.28731. Epub 2014 Apr 18. PMID: 24752448.
Dragomir A, Côté R, Roy L, Blais L, Lalonde L, Bérard A, Perreault S. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care. 2010 May;48(5):418-25. doi: 10.1097/MLR.0b013e3181d567bd. PMID: 20393367.